Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer by Perez, Edith A. et al.
Title
Relationship between tumor biomarkers and efficacy in
MARIANNE, a phase III study of trastuzumab emtansine ±
pertuzumab versus trastuzumab plus taxane in HER2-positive
advanced breast cancer
Author(s)
Perez, Edith A.; de Haas, Sanne Lysbet; Eiermann, Wolfgang;
Barrios, Carlos H.; Toi, Masakazu; Im, Young-Hyuck; Conte,
Pier Franco; Martin, Miguel; Pienkowski, Tadeusz; Pivot,
Xavier B.; Burris, Howard A.; Stanzel, Sven; Patre, Monika;
Ellis, Paul Anthony




This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative
Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to




RESEARCH ARTICLE Open Access
Relationship between tumor biomarkers
and efficacy in MARIANNE, a phase III study
of trastuzumab emtansine ± pertuzumab
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Abstract
Background: The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine
(T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these
and other trials showed that T-DM1–associated survival benefits were observed across biomarker subgroups tested
in these trials. Prespecified, exploratory analyses of the phase III MARIANNE study examined the effects of HER2-
related biomarkers on PFS in patients administered T-DM1 in the first-line MBC setting.
Methods: In MARIANNE, patients with previously untreated HER2-positive MBC were randomized (1:1:1) to
trastuzumab plus taxane, T-DM1 plus placebo, or T-DM1 plus pertuzumab. Biomarker subgroups included HER2
and HER3 mRNA expression levels (≤median vs. >median), HER2 staining intensity (IHC 3+ vs. 2+ vs. 0/1+), PIK3CA
status (mutated vs. non-mutated), PTEN H-score (≤median vs. >median), and PTEN protein expression level (0 vs. 1+ vs.
2+ vs. 3+ vs. 4+). PFS was analyzed descriptively for each subgroup using Kaplan–Meier methodology. Additional
exploratory post-hoc analyses evaluated the effects of HER2 heterogeneity. Multivariate analyses were also performed.
Results: Median PFS was numerically longer for patients with HER2 mRNA levels >median versus ≤median across
treatment arms. In general, there were no predictive biomarkers of benefit for either T-DM1 treatment arm; most
hazard ratios were close to 1 with wide confidence intervals that included the value 1. Focal HER2 expression (IHC 3+
or IHC 2+) was present in 3.8% of patients and was associated with numerically shorter PFS in the T-DM1–containing
treatment arms versus trastuzumab plus taxane. Compared with non-mutated PIK3CA, mutated PIK3CA was associated
with numerically shorter median PFS across treatment groups. Post-hoc multivariate analysis showed HER2 mRNA
expression and mutated PIK3CA were prognostic for PFS (P≤ 0.001 for both biomarkers).
Conclusions: In MARIANNE, biomarkers related to the HER2 pathway did not have predictive value for PFS
when comparing T-DM1 (with or without pertuzumab) with trastuzumab plus taxane. However, HER2 mRNA
level and PIK3CA mutation status showed prognostic value. Evaluation of other potential biomarkers, including
immune markers, is ongoing.
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Background
Therapeutic agents directed against human epidermal
growth factor receptor 2 (HER2) have been developed to
target the 15–20% of breast tumors that overexpress the
HER2 protein [1–3]. Trastuzumab emtansine (T-DM1)
is an antibody–drug conjugate that links the anti-HER2
humanized monoclonal antibody trastuzumab to DM1, a
cytotoxic microtubule inhibitor. The trastuzumab por-
tion delivers DM1 directly to HER2-overexpressing
tumor cells, minimizing off-target effects [4]. Like trastu-
zumab, T-DM1 inhibits HER2 shedding, induces
antibody-dependent cellular cytotoxicity, and inhibits
phosphoinositide 3-kinase (PI3K)/Akt pathway-mediated
cell signaling [5].
T-DM1 is indicated in many countries for single-agent
treatment of patients with HER2-positive metastatic
breast cancer (MBC) previously treated with trastuzumab
and a taxane (separately or in combination). The clinical
benefits of single-agent T-DM1 therapy in patients with
previously treated advanced breast cancer were estab-
lished in the phase III EMILIA and TH3RESA trials [6, 7].
In EMILIA, T-DM1 was compared with capecitabine plus
lapatinib in patients with HER2-positive MBC previously
treated with trastuzumab and a taxane (separately or in
combination). In TH3RESA, T-DM1 was compared with
treatment of physician’s choice (TPC) in patients previ-
ously treated with trastuzumab and lapatinib in the
advanced setting and a taxane in any setting. In both stud-
ies, T-DM1 was associated with statistically significant
improvements in both progression-free survival (PFS) and
overall survival (OS) relative to the respective control
regimen [6–8].
Given the survival benefits conferred by T-DM1 in
previously treated MBC [6–8], the phase III MARI-
ANNE study sought to explore the efficacy and safety of
T-DM1 in patients with previously untreated HER2-
positive advanced breast cancer [9]. Patients in MARI-
ANNE were randomized 1:1:1 to trastuzumab plus
taxane (hereafter referred to as “control”), T-DM1 plus
placebo (hereafter referred to as “T-DM1”), or T-DM1
plus pertuzumab (T-DM1 + P). Median PFS was
13.7 months in the control group compared with
14.1 months and 15.2 months in the T-DM1 and
T-DM1 + P groups, respectively. Based on these results,
T-DM1 treatment (with or without pertuzumab) resulted
in non-inferior, but not superior, PFS relative to control
(stratified hazard ratio [HR] = 0.91, 97.5% confidence inter-
val [CI] 0.73–1.13, P = 0.31 for T-DM1 vs. control; 0.87,
97.5% CI 0.69–1.08, P = 0.14 for T-DM1+ P vs. control).
The relationship between the expression of specific
biomarkers and efficacy of T-DM1 has been examined in
EMILIA [10], TH3RESA [11], and a series of phase II
trials investigating patients with HER2-positive MBC
[12–14]. In general, the collective data from these stud-
ies demonstrated that there were no predictive bio-
markers for T-DM1 survival benefits. These studies also
suggested that high expression of HER2 mRNA levels
(greater than median levels [>median]) was a positive
prognostic marker, associated with both a better PFS
and OS benefit in EMILIA. However, although a predict-
ive value of HER2 mRNA for T-DM1 treatment was ob-
served in both EMILIA and THERESA, results were not
fully consistent regarding endpoints observed, and may
have been influenced by factors like treatment line and
comparator (control) regimen. The relevance of HER2
mRNA prompted questions about whether HER2 ex-
pression heterogeneity impacts treatment response.
Although PI3K pathway aberrations have been impli-
cated in resistance to HER2-targeted therapies such as
trastuzumab [15, 16] and lapatinib [17], results from bio-
marker analyses of EMILIA study data have shown that
T-DM1 was associated with numerical improvements in
median PFS, median OS, and overall response rate rela-
tive to capecitabine plus lapatinib, irrespective of PI3K
catalytic subunit alpha (PIK3CA) mutation status [10].
Preclinical studies (cell lines and xenograft models) have
also shown that T-DM1 exhibits potent activity in the
presence of PIK3CA mutations [10]. Conversely, among
patients randomized to capecitabine plus lapatinib in
EMILIA, median PFS and OS were numerically shorter
in patients with PIK3CA-mutated versus PIK3CA–
non-mutated tumors [10]. In TH3RESA, T-DM1–
treated patients had similar median PFS regardless of
PIK3CA mutation status. Median PFS was also compar-
able in TPC-treated patients with tumors expressing mu-
tated versus non-mutated PIK3CA, of which 80% received
trastuzumab-based treatment [11].
In MARIANNE, the impact of hormone receptor sta-
tus on PFS has been reported previously, and no differ-
ences in PFS were seen between patients who were
hormone receptor–positive and –negative [9]. However,
the MARIANNE study also provides an opportunity to
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examine whether T-DM1 treatment of previously un-
treated HER2-positive MBC could overcome the poor
prognosis of mutated PIK3CA, assess the prognostic and
predictive value of HER2 mRNA, and potentially identify
associations with other biomarkers. To this end, the
purpose of the exploratory analyses presented herein
was to examine the association between biomarkers
related to the HER2 pathway and PFS in patients from
the phase III MARIANNE study.
Methods
Study design and patients
The MARIANNE (NCT01120184) study design and pri-
mary analysis results have been published elsewhere [9].
In brief, MARIANNE is a phase III, international study
of patients with centrally-confirmed HER2-positive unre-
sectable, progressive, or recurrent locally advanced or
previously untreated MBC (advanced breast cancer) and
no prior treatment for advanced disease. Patients were
randomized (1:1:1) to control (trastuzumab plus taxane
[docetaxel or paclitaxel]), T-DM1, or T-DM1+ P.
The primary efficacy endpoint was PFS, which was de-
termined by an independent review committee (IRC).
PFS was defined as the time from randomization to the
first occurrence of IRC-assessed disease progression (per
Response Evaluation Criteria in Solid Tumors version
1.1 [18]) or death from any cause. Protocol-specified ex-
ploratory biomarker analyses were conducted to evaluate
the association between PFS and molecular markers re-
lated to its mechanism of action (e.g., HER pathway
effectors).
The MARIANNE study protocol, including a descrip-
tion of the exploratory biomarker analyses, was ap-
proved by the institutional review board/ethics
committee at each participating center. The trial con-
formed to Good Clinical Practice guidelines, the Declar-
ation of Helsinki, and applicable local laws. All patients
provided written informed consent, which included con-
sent for biomarker analyses. Analysis of PTEN protein
expression required additional tissue and therefore a
separate written patient consent. These analyses were
conducted only in patients who provided this consent.
Biomarker assessments
Samples from the primary or metastatic tumor were
submitted to a central laboratory for the determination
of HER2 status by immunohistochemistry (IHC; PATH-
WAY anti-HER-2/neu [4B5] assay, Ventana Medical Sys-
tems, Inc.) and in situ hybridization (INFORM HER2
Dual ISH assay, Ventana Medical Systems, Inc.). HER2
distribution was also assessed (not prespecified); patients
with either IHC 2+ or IHC 3+ staining were categorized
according to whether HER2 staining was focal (10–29%),
heterogeneous (30–79%), or homogeneous (≥80%), based
on the total percentage of cells stained with 2+ and 3+
intensity. Tissue samples used for HER2 testing were
also used for additional biomarker analyses.
HER2 mRNA level, HER3 mRNA level, HER2 staining
intensity, PIK3CA status, PTEN H-score, and PTEN
protein level were all prespecified as biomarkers for in-
clusion in this exploratory analysis. Analysis of PTEN
protein expression required a separate written patient
consent, as described above, and optional donation of
additional tumor samples, which were provided as add-
itional material from the same tissue sample originally
provided.
The methods used for the biomarker assessments have
been described in detail elsewhere [10, 11]. Briefly, HER2
and HER3 mRNA expression levels were measured using
quantitative real-time polymerase chain reaction (cobas®
4800 System, Roche Molecular Diagnostics) and reported
as a ratio in reference to glucose-6-phosphate dehydro-
genase expression. PIK3CA mutation status was deter-
mined using the cobas® PIK3CA Mutation Test (Roche
Molecular Diagnostics) and cobas® 4800 System (Roche
Molecular Diagnostics). The analysis of cytoplasmic PTEN
protein expression was assessed via IHC (138G6 rabbit
monoclonal antibody, Cell Signaling Technology®). The
analysis of PIK3CA mutation status was performed at His-
toGeneX NV (Berchem, Belgium). Central HER2 testing
was performed by multiple pathologists at Targos Molecu-
lar Pathology GmbH (Kassel, Germany). Additional bio-
marker analyses were also performed by Targos Molecular
Pathology GmbH.
Statistical methods
This exploratory analysis evaluated the potential prog-
nostic and predictive value of HER2 mRNA expression
level (≤median vs. >median), HER3 mRNA expression
level (≤median vs. >median), HER2 staining intensity
(IHC 3+ vs. 2+ vs. 0/1+), PIK3CA status (mutated vs.
non-mutated), PTEN H-score (≤median vs. >median),
and PTEN protein level (0 vs. 1+ vs. 2+ vs. 3+ vs. 4+) as
biomarkers for PFS. Predictive biomarker effects were
evaluated based on PFS HRs and associated CIs within
biomarker-defined subgroups, while prognostic effects
were evaluated across treatment arms. PFS was analyzed
descriptively for each biomarker subgroup using the
Kaplan–Meier method. A Cox proportional hazards re-
gression model was used to estimate HRs and 97.5% CIs
(choice of CI coverage probability is due to the hierarch-
ical statistical testing procedure employed in this study,
applying parallel statistical testing of T-DM1 vs. control
and T-DM1 + P vs. control, see [9]).
Biomarker status was evaluated based on baseline tumor
samples. As in prior T-DM1 studies [10–14, 19], bio-
marker subgroups for HER2 and HER3 were defined using
the median distribution values for mRNA expression
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(≤median vs. >median). To further understand the associ-
ation between HER2 expression and PFS, patients were
also grouped by the intensity of HER2 staining (IHC 3+
vs. 2+ vs. 0/1+). For the analysis of PIK3CA, tumors were
classified as either mutated (presence of ≥1 mutation) or
non-mutated. PTEN subgroups were defined using the
median H-score [20] value (≤median vs. >median) and
predefined protein expression categories assigned based
on the percentage of tumor cells with cytoplasmic staining
relative to adjacent, internal, non-tumor control cells (0
[no staining] vs. 1+ [decreased] vs. 2+ [slightly decreased]
vs. 3+ [equal] vs. 4+ [increased]). A post-hoc analysis was
conducted to understand whether HER2 expression het-
erogeneity affected PFS. In this analysis, patients with IHC
2+ and IHC 3+ staining were grouped by HER2 distribu-
tion (focal, heterogeneous, or homogeneous). In addition,
a data-driven (post-hoc) analysis of PFS was performed in
which the subgroup of patients with at least one bio-
marker shown to negatively impact treatment response to
T-DM1 were compared with the subgroup comprised of
the remaining study patients. Additionally, the impact of
the combination of both HER2 mRNA (≤median
and > median) and PIK3CA mutation (mutated and non-
mutated) on PFS was evaluated in combination subgroups
as part of the post-hoc data-driven analyses.
The effect of HER2 mRNA (analyzed as a categorical
variable using the median mRNA expression value as a
cut-off ) and PIK3CA status (mutated vs. non-mutated)
on PFS was also examined in a post-hoc multivariate
analysis using two Cox proportional hazards regression
models. The first model, which was fully adjusted, in-
cluded the following additional covariates: study treat-
ment, prior treatment with taxane and/or trastuzumab
(yes/no), prior treatment with anthracyclines (yes/no),
world region, presence/absence of visceral disease, pres-
ence/absence of measurable disease, disease-free inter-
val, baseline Eastern Cooperative Oncology Group
performance status score, hormone receptor status, ther-
apy setting, breast cancer staging, and menopausal sta-
tus. The second multivariate analysis approach also
started with the fully adjusted model, then a stepwise
backward variable selection procedure was applied. A
P-value threshold of 0.05 was used to decide whether a
covariate should be retained in the model or removed.
The treatment effect was kept “fixed” (i.e., study treat-
ment was not allowed to be removed from the model at
any step). Goodness of fit of the two models was
assessed by computing Akaike’s Information Criterion
(AIC) [21]. Smaller AIC values indicate relatively better
model performance. As all data reported herein derive
from exploratory analyses, the P-values as well as the
HRs and associated 95% CIs from the multivariate ana-
lyses are provided only for illustrative purposes and only
for the model with the smaller AIC value.
Results
Patients and demographics
A total of 365 patients were randomized to control,
367 to T-DM1, and 363 to T-DM1 + P. HER2 status
was determined using samples derived from the pri-
mary tumor for 77% (844/1095) of patients and from
a metastatic tumor for 11% (123/1095) of patients;
tumor location (primary vs. metastatic) was not
known in 12% (128/1095) of patients. Biomarker
availability was generally balanced across treatment
arms (Table 1), with ≥90.0% of patients providing data
for the analyses of HER2 mRNA, HER3 mRNA, and
PIK3CA status. Because the evaluation of PTEN pro-
tein expression was performed on an additional tissue
sample, the donation of which was optional and re-
quired separate written consent, samples from fewer
(49.5%) patients were available for the analysis of this
biomarker. Distribution of tumor location (primary,
metastatic, or unknown) was similar for the assess-
ment of each biomarker (HER2 mRNA, HER3 mRNA,
PIK3CA status, and PTEN) and was well balanced
across the three treatment arms (data not shown).
Median baseline values for HER2 mRNA, HER3
mRNA, and PTEN protein expression and the propor-
tion of patients with tumors expressing mutated
PIK3CA (26–28%) were equally distributed across
treatment arms. HER2 distribution was equally dis-
tributed across the treatment arms; for example, 3%,
3%, and 4% of patients in the control, T-DM1, and
T-DM1 + P arms, respectively, had focal HER2 distri-
bution (Table 1).
Impact of biomarker expression on PFS
Of the biomarkers examined, in general, none revealed a
subgroup with clear treatment benefit for T-DM1 or
T-DM1 + P relative to control with regard to PFS (Fig. 1a
and b). HRs comparing PFS between T-DM1 and
T-DM1 + P versus control within each biomarker sub-
group remained close to the overall HRs for these treat-
ment comparisons, except for PTEN H-score > median.
No biomarker subgroup was associated with substan-
tially longer median PFS for T-DM1 + P versus T-DM1,
with all HRs clustered around the overall HR of 0.81
(Fig. 1c). Review of these data should consider that bio-
marker subgroup sample sizes were small for some sub-
groups and the CIs for the respective HRs were wide
and included the value 1.
In all treatment arms, HER2 mRNA levels >median
versus ≤median were associated with numerically lon-
ger PFS (control: 15.9 vs. 12.4 months; T-DM1: 18.6
vs. 10.2 months; T-DM1 + P: 18.7 vs. 14.5 months)
(Fig. 2a). Thus, HER2 mRNA was found to be prog-
nostic of PFS benefit within all treatment arms. Ex-
pression of mutated versus non-mutated PIK3CA was
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associated with numerically shorter PFS within all
three treatment arms (Fig. 2b).
Despite these differences, as noted above, HER2 mRNA
and PIK3CA did not have predictive value for a treatment
benefit in response to T-DM1 compared with control, as
none of the biomarker subgroups in the population of pa-
tients treated with T-DM1 had a greater PFS benefit com-
pared with the control arm; however, some numerical
differences between treatment arms were notable. Among
patients with HER2 mRNA ≤median, median PFS was nu-
merically higher for T-DM1+ P versus control, but not for
T-DM1 versus control. Among patients with >median
HER2 mRNA, median PFS was numerically higher for
both T-DM1 treatment arms compared with control. In
the analysis of PIK3CA, median PFS was numerically
higher in the control arm compared with both T-DM1
treatment arms for patients with mutated PIK3CA. By
contast median PFS was numerically lower in the control
arm compared with the T-DM1 treatment arms for those
with non-mutated PIK3CA.
Patients who received T-DM1 (alone or in combin-
ation with pertuzumab) had a median PFS that was nu-
merically larger, with PTEN H-scores >median (21.5 and
21.2 months, respectively) versus those with H-scores
≤median (10.4 and 12.5 months, respectively) (Fig. 1).
For patients who received control, there was no numer-
ical difference in median PFS by PTEN protein level sta-
tus (14.9 months in patients with PTEN H-score >
median and ≤median values). The PTEN categories (e.g.,
none/slightly decreased/decreased vs. equivalent/increased)
did not show a consistent trend in association with PFS
outcome across treatment arms.
Table 1 Biomarker status at baseline among patients in the intent-to-treat population of the MARIANNE study
Trastuzumab + taxane




(T-DM1 + P) (N = 363)a
HER2 mRNA
n (%) 330 (90) 339 (92) 330 (91)
Median (range) 57.28 (1.9–4182.1) 56.89 (0.9–3615.6) 61.61 (2.1–3281.2)
HER2 status, n (%)
ISH-positive/IHC 3+ 294 (81) 305 (83) 295 (81)
ISH-positive/IHC 2+ 27 (7) 25 (7) 27 (7)
ISH-positive/IHC 1+, 0 or unknown 5 (1) 2 (1) 3 (1)
ISH-negative/IHC 3+ 7 (2) 5 (1) 7 (2)
ISH-negative or unknown/IHC 2+ 0 0 2 (1)
ISH unknown/IHC 3+ 32 (9) 30 (8) 29 (8)
HER3 mRNA
n (%) 331 (91) 342 (93) 332 (91)
Median (range) 1.88 (0.1–33.1) 1.57 (0.1–52.7) 1.71 (0.1–26.0)
PIK3CA status
n (%) 326 (89) 332 (90) 328 (90)
Mutated, n (%) 83 (25) 92 (28) 88 (27)
Non-mutated, n (%) 243 (75) 240 (72) 240 (73)
PTEN H-score
n (%) 182 (50) 181 (49) 179 (49)
Median (range) 135.0 (0.0–310.0) 180.0 (0.0–370.0) 160.0 (0.0–380.0)
HER2 distribution
n (%)b 360 (99) 365 (99) 360 (99)
Focal (10–29%), n (%) 14 (4) 12 (3) 15 (4)
Heterogeneous (30–79%), n (%) 35 (10) 37 (10) 33 (9)
Homogeneous (≥80%), n (%) 311 (86) 316 (87) 312 (87)
aIntention-to-treat population
bOnly includes patients who were IHC 2+ or IHC 3 +
Biomarker prevalence reported here is based on the number of patients with data available for each marker. HER2 human epidermal growth factor receptor 2, IHC
immunohistochemistry, ISH in situ hybridization, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, P pertuzumab, PTEN phosphatase and tensin homolog,
T-DM1 trastuzumab emtansine
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Impact of HER2 expression levels and heterogeneity on
PFS
Median PFS was numerically longer in patients with
IHC 3+ versus IHC 2+ HER2 staining; this difference
was more pronounced among patients randomized to
T-DM1 or T-DM1 + P versus control (Table 2).
The association between HER2 expression heterogen-




Fig. 1 PFS by biomarker status. a T-DM1 versus control. b T-DM1 plus pertuzumab versus control. c T-DM1 plus pertuzumab versus T-DM1. CI
confidence interval, HER human epidermal growth factor receptor, HR unstratified hazard ratio, PFS progression-free survival, PI3K phosphoinositide 3-kinase,
PTEN phosphatase and tensin homolog, T-DM1 trastuzumab emtansine. *PI3K and PTEN category “other” represents patients with no PI3K mutation and no
decrease in PTEN, or one of these in combination with an unknown for the other marker (e.g., no PI2K mutation and unknown PTEN status)
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exploratory analysis. Of the 1004 patients with IHC 3+
HER2 staining, 28 (2.8%) exhibited focal expression, 118
(11.8%) exhibited heterogeneous expression, and 858
(85.5%) exhibited homogeneous expression. When 2+
and 3+ staining intensity was considered in IHC2+ or
IHC3+ patients, homogeneous staining was associated
with numerically longer median PFS than focal/hetero-
geneous staining. For IHC 3+ patients, for whom only
3+ intensity staining was considered, focal HER2 ex-
pression was present in a small subgroup of patients
(3.8% [41/1085]), and was associated with numerically
shorter median PFS in the two T-DM1 treatment
arms versus the control arm (Table 2).
Post-hoc, data-driven analysis of subgroups defined by
the presence/absence of biomarkers with negative impact
on PFS
Given the numerical decrease in PFS associated with
PIK3CA mutation, low HER2 mRNA expression (≤me-
dian), and focal HER2 expression, especially in patients re-
ceiving trastuzumab emtansine, a post-hoc, data-driven
analysis of PFS was performed evaluating patient sub-
groups based on the combined presence and absence of
these biomarkers (Fig. 3). In this analysis, the Kaplan–
Meier curves of all three treatment arms were largely
overlapping for those patients with selected biomarkers,
and for those without. For all three treatment groups,
however, patients without these selected biomarkers
(i.e., those with non-mutated PIK3CA, >median HER2
mRNA expression, and non-focal HER2 expression)
experienced better PFS independent of treatment arm.
Therefore, this analysis did not reveal a subset of pa-
tients who experienced treatment benefit in terms of
PFS when receiving T-DM1.
Post-hoc analysis of HER2 mRNA and PIK3CA mutation
subgroups in patients with de novo MBC
In MARIANNE, 38% of patients (410/1088) had de novo
disease (defined as patients diagnosed with metastatic
disease within 30 days from the date of initial diagnosis),
with the percentage of patients with de novo MBC being




Fig. 2 Statistical analysis of PFS in subgroups defined by a HER2 mRNA expression (≤median vs. >median), b PIK3CA status (mutated vs. non-
mutated), and c PIK3CA status in combination with HER2 mRNA expression. See Additional file 1: Tables S2 and S3 for a table of PFS values and
hazard ratios. CI confidence interval, HER human epidermal growth factor receptor, HR unstratified hazard ratio, PIK3CA phosphoinositide 3-kinase
catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine
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T-DM1, and 36.1% T-DM1 + P). The tumor tissue col-
lected from these patients was fresh (i.e., not archival)
and had not been affected by prior treatments; there-
fore, it should reflect a reliable biomarker status for
the analysis of treatment effects (see Additional file 1:
Figure S1). Interpretation of these results showed that
the prognostic value of HER2 mRNA and PIK3CA
was inconsistent between the two T-DM1 treatment
arms. Therefore, these results were inconclusive.
However, it should be acknowledged that the biology
of de novo disease may differ from that of previously
treated disease.
Multivariate analysis evaluating the effects of HER2 mRNA
expression and PIK3CA status on PFS
Compared with the fully adjusted multivariate model,
the stepwise backward variable selection model was bet-
ter in terms of goodness of model fit (i.e., had a smaller
AIC value). Per the final model resulting from applying
the stepwise backward variable selection procedure,
HER2 mRNA expression and PIK3CA mutation status
were both prognostic for PFS (P ≤ 0.001 for both). The
P-value for the treatment effect was P = 0.057. The
complete list of covariates that remained in the final
model and associated P-values as well as the HRs and
associated 95% CIs is summarized in Additional file 1:
Table S1.
Overlap between PIK3CA status, HER2 mRNA expression,
and HER2 IHC staining pattern and impact on PFS
Given the contradicting results on the prognostic value
of PIK3CA mutation in MARIANNE versus TH3RESA
and EMILIA, further evaluation of PIK3CA mutation
status and overlap with other biomarkers was under-
taken. It should be noted that these analyses and inter-
pretation of these results are limited due to being
post-hoc and data-driven and because they are investi-
gating effects in a sub-subgroup (i.e., a smaller and more
selected group of patients). Of the patients with both
HER2 IHC expression and PI3KCA mutation status
available, a higher PIK3CA mutation rate was observed
in patients with focal or heterogeneous HER2 expression
(41.9%; 57/136) compared to those with homogeneous
HER2 expression (24.0%; 202/840) (Table 3). Among 501
patients with ≤median HER2 mRNA levels, 484 also had
PIK3CA mutation status available; in 35.3% (171/484) of
these patients, PIK3CA was mutated. This was higher
than the prevalence in the 467 of 498 patients who had
>median HER2 mRNA levels and PIK3CA mutation sta-
tus available; of these 18.4% (86/467) had mutated
PIK3CA (Table 3). The efficacy of single-agent T-DM1
seemed to be independent of PIK3CA status in the sub-
group of patients with HER2 mRNA >median (Fig. 2c)
in contrast to patients with HER2 mRNA ≤median.
However, for T-DM1 + P, the impact of PIK3CA mu-
tation seemed less different between the HER2 mRNA
subgroups than that observed with single-agent
T-DM1.
Discussion
In this exploratory analysis of biomarker data from the
phase III MARIANNE study, none of the evaluated bio-
markers (all of which are related to the HER2 pathway)
showed predictive value for PFS benefit with T-DM1
treatment alone or in combination with pertuzumab ver-
sus control in this group of patients with HER2-positive
Fig. 3 Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers;*.*Biomarkers were considered
negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS, specifically, these included
expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with non-
mutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative
markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth
factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine
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advanced breast cancer previously untreated in the ad-
vanced setting. HER2 mRNA expression was prognostic
of PFS, as HER2 mRNA expression levels >median were
associated with numerically longer median PFS across
all treatment arms. PIK3CA status was also prognostic,
with mutated PIK3CA associated with numerically
shorter median PFS for all study regimens compared
with non-mutated PIK3CA. The prognostic value of
HER2 mRNA expression and PIK3CA status was con-
firmed in a post-hoc multivariate analysis.
The finding that HER2 mRNA levels >median were
prognostic for clinical benefit of HER2-targeted therapy
is consistent with the biomarker analysis from the
CLEOPATRA study in which patients received first-line
treatment of HER2-positive MBC with pertuzumab plus
trastuzumab plus docetaxel or placebo plus trastuzu-
mab plus docetaxel (control) [22]. In CLEOPATRA,
high HER2 mRNA expression was associated with bet-
ter clinical outcome based on data pooled across treat-
ment arms. Interestingly, in the exploratory biomarker
analyses of EMILIA and TH3RESA, which recruited pa-
tients with previously treated HER2-positive MBC,
single-agent T-DM1 was also associated with numeric-
ally longer PFS in the subgroup of patients with higher
versus lower levels of HER2 mRNA [10, 11]. However,
in the control arm of TH3RESA (TPC), but not EMI-
LIA (capecitabine plus lapatinib), median PFS was simi-
lar for patients with ≤median and > median HER2
mRNA expression. Therefore, the ability to differentiate
clinical benefit derived from T-DM1 versus control in
the high HER2 mRNA subgroup seemed to depend on
treatment line (first line vs. later line) and comparator
regimen.
Across treatment arms, we did not observe a consist-
ent trend for the PTEN. Among T-DM1 treated patients,
there was a trend toward numerically greater PFS with
higher PTEN H-scores, however, this was not observed
in the control group. Multiple studies have evaluated the
association between PTEN protein expression and re-
sponse to anti-HER2 therapy and many also have shown
no influence of PTEN expression on outcome. In both
TH3RESA and EMILIA, patients with higher and lower
PTEN protein levels experienced a PFS benefit from
T-DM1 [10, 11]. The phase III North Central Cancer
Treatment Group (NCCTG) N9831 trial compared
doxorubicin and cyclophosphamide followed by weekly
paclitaxel (arm A) with the same regimen plus a year of
sequential trastuzumab (arm B) or concurrent trastuzu-
mab (arm C, with trastuzumab started on the same day
as weekly paclitaxel). This study found a benefit of adju-
vant trastuzumab on disease-free survival for patients
with HER2-positive breast cancer, independent of tumor
PTEN status [23]. In the CLEOPATRA study, there was
a consistent PFS benefit from pertuzumab plus trastuzu-
mab plus docetaxel versus placebo plus trastuzumab
plus docetaxel regardless of PTEN status; however, low
cytoplasmic PTEN was associated with a worse OS out-
come for the pertuzumab arm [22].
In this biomarker analysis of MARIANNE, as well as
the biomarker analysis of CLEOPATRA [22], mutated
PIK3CA was associated with worse clinical outcome in
terms of PFS across all treatment arms, and the
Table 3 Overlap of HER2 mRNA level, PI3K mutation status, and HER2 IHC staining pattern biomarker subgroups
Biomarker subgroup Patients n (%a)
HER2 mRNA and PI3K status available (N = 951) HER2 mRNA level PI3K mutation status
≤median (n = 484) Mutated 171 (35.3)
Non-mutated 313 (64.7)
>median (n = 467) Mutated 86 (18.4)
Non-mutated 381 (81.6)
HER2 mRNA and HER2 IHC expression available (N = 989) HER2 mRNA level HER2 IHC expression
≤median (n = 495) Focal/heterogeneous 114 (23.0)
Homogeneous 381 (77.0)
>median (n = 494) Focal/heterogeneous 19 (3.8)
Homogeneous 475 (86.6)
PI3K mutation status and HER2 IHC expression available (N = 976) HER2 IHC expression PI3K mutation status
Focal/heterogeneous (n = 136) Mutated 57 (41.9)
Non-mutated 79 (58.1)
Homogeneous (n = 840) Mutated 202 (24.0)
Non-mutated 638 (76.0)
aPercentage based on number of patients with both biomarkers available and calculated within subgroups. HER2 mRNA missing n = 96; PI3K mutation status
missing n = 109; IHC H score missing n = 10
HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PI3K phosphoinositide 3-kinase
Perez et al. BMC Cancer          (2019) 19:517 Page 10 of 14
difference in PFS between patients with mutated and
non-mutated PIK3CA was greatest in the T-DM1 treat-
ment arms. In contrast, in both EMILIA and TH3RESA,
the positive effects of T-DM1 on clinical outcome were
observed in patients with mutated and non-mutated
PIK3CA [10, 11]. The reasons for the discrepant results
across these phase III studies are unclear. However, pa-
tients in MARIANNE did not receive prior treatment
for advanced disease, while patients in EMILIA and
TH3RESA were pretreated. This may have influenced
the biomarker status, which was assessed from archival
samples from the primary tumor in 80% of patients in
the EMILIA and TH3RESA trials and, as a result, may
not reflect the biomarker status at study start in a
later-line disease setting. In MARIANNE, more patients
had non-archival tissue, as 37% of patients had de novo
disease. Another explanation for the conflicting observa-
tions could be the association between mutant PIK3CA
and HER2 mRNA expression levels in the tumors of
MARIANNE patients, which was observed in a post-hoc
analysis evaluating overlap of biomarkers across patients.
In MARIANNE, it was observed that a PIK3CA muta-
tion was much more prevalent in tumors with low
HER2 mRNA expression (35.3%) compared with those
with high HER2 mRNA expression (18.4%). In line with
these associations, a higher PIK3CA mutation rate was
seen in focal or heterogeneous (41.9%) versus homoge-
neous (24.0%) tumors. A similar association was ob-
served in CLEOPATRA (unpublished data), suggesting
that this phenotype may be genuine and does not reflect
a bias in biomarker prevalence among MARIANNE pa-
tients. Higher prevalence of PIK3CA mutation in low
HER2 mRNA expressing tumors was not seen in EMI-
LIA and TH3RESA, but it is possible that analyses
resulted in patient subgroups with imbalances in bio-
marker expression, as PIK3CA mutation data were not
available for all patients in those trials.
Although this finding from MARIANNE should be inter-
preted with caution, one could hypothesize a plausible bio-
logical rationale for this discrepancy. It is unknown
whether the co-occurrence of these poor prognostic
markers is found only at the tumor level, or if it is also
found at the single-cell level. Findings from an in situ
single-cell analysis suggest that, while mutated PIK3CA and
HER2 gene amplifications occurs individually in
HER2-positive breast cancer, following chemotherapy, the
cell population containing both alterations was enriched in
patients with resistant disease [24]. One could hypothesize
that treatment history influences the co-occurrence of mu-
tated PIK3CA and HER2 overexpression on a single-cell
level (Fig. 4). In a treatment-naive tumor, HER2 might be
heterogeneously amplified, with PIK3CA mutation occur-
ring more commonly in HER2-negative rather than
HER2-positive cells, which makes a tumor with low HER2
expression (as observed in tumors with greater HER2 het-
erogeneity) more likely to also show a PIK3CA mutation.
However, following treatment, PIK3CA mutation may be
enriched in HER2-amplified tumor cells (e.g., as a resistance
mechanism to HER2-targeted therapy). Thus, a PIK3CA
mutation would be detected in the primary tumor, but the
Fig. 4 Hypothesized influence of treatment history on co-occurrence of mutated PIK3CA and HER2 overexpression. HER human epidermal growth
factor receptor, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, T-DM1 trastuzumab emtansine
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impact of PIK3CA mutation on clinical benefit when re-
ceiving T-DM1 may be different in these two situations. As
T-DM1 binds to HER2, theoretically, T-DM1 is more likely
to kill a PIK3CA-mutated tumor cell with co-occurring
HER2 amplification versus a HER2-negative, PIK3CA-mu-
tated cell, despite the fact that the tumor as a whole is
HER2-positive and PIK3CA-mutated. Our post-hoc ana-
lyses assessing T-DM1 treatment effects in patients with
PIK3CA mutated tumors and a high versus low HER2
mRNA level seem to support this hypothesis, but no firm
conclusions can be drawn from these exploratory analyses.
As hypothesized above, the genetic composition of the
tumor may change from the first-line to later-line setting
and affect the impact of the PIK3CA mutation on outcome
in different disease settings, as observed between the
MARIANNE, EMILIA and TH3RESA studies.
Because patients randomized to T-DM1–based treat-
ment in MARIANNE did not receive systemic chemo-
therapy, HER2 heterogeneity was hypothesized to be a
main driver of response in T-DM1–treated patients.
Evaluation of the HER2 staining patterns in MARIANNE
showed that focal or heterogeneous HER2 staining pat-
terns were infrequently seen in patients with IHC 3+ tu-
mors (2.8 and 11.8%, respectively), whereas a much
higher proportion of patients with IHC 2+ tumors (48.1%)
exhibited focal staining. These findings are consistent with
previous studies, in which more HER2 heterogeneity was
reported in IHC 2+ versus IHC 3+ tumors [25–27]. In a
data-driven, post-hoc analysis, we categorized patients ac-
cording to the pattern of HER2 staining using the total of
cells stained with 2+ and 3+ intensity, and found median
PFS to be numerically shorter in T-DM1–treated patients
with focal versus homogeneous HER2 expression (6.4 vs.
14.7months for T-DM1 and 7.5 vs. 17.8months for
T-DM1 + P). We observed low levels of HER2 gene ampli-
fication in patients with heterogeneous HER2 staining in
MARIANNE, a phenomenon that has previously been re-
ported [26]. Moreover, it is known that intra-tumoral het-
erogeneity commonly results from chromosomal
instability, which is itself associated with poor prognosis
[28]. Thus, the numerically shorter median PFS observed
in MARIANNE patients with tumors exhibiting
non-homogeneous HER2 distribution may relate to both
insufficient target (owing to low HER2 gene copy num-
ber/expression) and to the fact that heterogeneous tumors
are inherently unstable (and thus predisposed to poorer
clinical outcomes). The shorter median PFS in focal sub-
groups was more pronounced in patients who received
T-DM1–containing treatment compared with the control
arm, which may suggest a larger impact of an insufficient
target in the absence of systemic chemotherapy.
As noted above, the evaluation of co-occurrence of
biomarkers in MARIANNE showed that focal/heteroge-
neous tumors were more likely to be PIK3CA-mutated
(41.9%) versus those with homogeneous HER2 expres-
sion (24.0%) and that tumors with low (≤median) HER2
mRNA levels were also more likely to be PIK3CA-mu-
tated (35.3%) compared with tumors with high (>me-
dian) HER2 mRNA levels (18.4%). These observations
suggest that there may be multiple cancer drivers within
individual tumors and that these can, in turn, influence
treatment response. While this phenomenon is intri-
guing, the expression of multiple, negative prognostic
biomarkers within a tumor makes it difficult to isolate
the individual contribution of each biomarker to clinical
outcomes. To understand if a more beneficial outcome
could be achieved in T-DM1–containing treatment arms
when biomarker subgroups with a hypothesized negative
impact on clinical outcome were excluded from the
evaluation, we conducted a post-hoc, data-driven ana-
lysis in which the PFS of patients with tumors character-
ized by the presence of non-mutated PIK3CA, high
HER2 mRNA levels, and heterogeneous or homoge-
neous distribution of HER2 was compared to the PFS of
all other patients. In this analysis, median PFS was com-
parable across treatment arms in patients with the posi-
tive biomarkers, suggesting that even if patients
expressing negative prognostic biomarkers had been ini-
tially excluded from MARIANNE, PFS outcomes in
T-DM1–treated patients would probably still not have
been superior to those observed in patients treated with
control. Additional studies are needed to further evalu-
ate the impact of negatively prognostic biomarkers on
the treatment effects of HER2-targeted therapy as well
as to understand the co-occurrence of such biomarkers
on a single-cell level and their associations with clinical
outcome across treatment lines. Such an analysis would
require serial sampling (i.e., samples taken at primary
diagnosis, recurrence, start of first-line treatment, etc.)
and development of more sensitive assays that allow the
analysis of tumor markers in blood, which is an easier
way to collect serial samples.
This exploratory analysis may be limited by the source
of the tumor samples; approximately 80% of the tissue
used in the MARIANNE biomarker analyses sampled
from primary tumors, with only ~ 10% deriving from
metastatic tumors. Biomarker status may have changed
between the primary and metastatic stages. However, the
use of primary tumor data is common, and biomarker
analyses of archival samples have shown that, for ex-
ample, HER2 mRNA expression is associated with clin-
ical outcome in T-DM1–treated patients across different
lines of therapy [10, 14, 22, 29], suggesting that HER2 is
relatively stable throughout the course of disease. This
may however differ for other markers. Another limita-
tion was the small sample sizes for some analyses–par-
ticularly the data-driven, post-hoc exploratory analyses
examining the co-occurrence of biomarkers–preclude
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definitive conclusions; thus, the data presented herein
should be considered hypothesis-generating. In addition,
our analyses only examined the impact of HER2-related
biomarkers on the primary efficacy endpoint of MARI-
ANNE (PFS), but not on OS, as OS data were immature
at the time of the MARIANNE primary analysis. Last,
evaluation of other potentially relevant biomarkers, such
as studies measuring immune markers, has yet to be
performed.
Conclusions
In the phase III MARIANNE study, biomarkers related
to the HER2 pathway (HER2 and HER3 mRNA expres-
sion levels, PIK3CA mutation status, PTEN H-score and
protein expression level, and tumor heterogeneity) were
not predictive of PFS benefit in MBC patients adminis-
tered first-line treatment with T-DM1 with or without
pertuzumab versus trastuzumab plus a taxane. However,
both HER2 mRNA level and PIK3CA mutation status
were shown to have prognostic value across all treat-
ment arms in both univariate and multivariate analyses.
Several hypotheses on biomarkers relating to the HER2
pathway, their overlap, evolution over time, and impact
on treatment outcome have been generated. Further re-
search, including the identification of patient character-
istics that may distinguish HER2-targeted treatment
responders from non-responders and analysis of the in-
fluence of tumor-infiltrating lymphocytes and immune
markers, is ongoing.
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